
    
      The overall goal of this protocol is to evaluate the biodistribution of [18F]MNI-958 also
      known as APN-0000455 or PM-PBB3, as a tau targeted radiopharmaceutical. The specific
      objectives are:

        -  To determine the radiation dosimetry of [18F]MNI-958

        -  To assess the safety and tolerability of a single dose of [18F]MNI-958
    
  